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ABSTRACT
Background: Immunogenicity, specifically the onset of
antibodies against tumour necrosis factor (TNF) blocking
agents, seems to play an important role in non-response
to treatment with these drugs.
Objectives: To assess the relation of clinical response of
ankylosing spondylitis (AS) to etanercept with etanercept
levels, and the presence of antibodies to etanercept.
Methods: Patients with AS were treated with etanercept
25 mg twice weekly, according to the international
Assessment in Ankylosing Spondylitis (ASAS) working
group consensus statement. Sera were collected at
baseline and after 3 and 6 months of treatment. Clinical
response was defined as a 50% improvement or as an
absolute improvement of 2 points on a (0–10 scale) Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI)
score. Functional etanercept levels were measured by a
newly developed ELISA, measuring the binding of
etanercept to TNF. Antibodies against etanercept were
measured with a two-site assay and antigen binding test.
Clinical data were used to correlate disease activity with
serum etanercept levels.
Results: In all, 53 consecutive patients were included.
After 3 months of treatment 40 patients (76%) fulfilled
the response criteria. Mean etanercept levels were
2.7 mg/litre and 3.0 mg/litre after 3 and 6 months
respectively. Characteristics and etanercept levels of
responders and non-responders were similar. No anti-
bodies to etanercept were detected with any of the
assays.
Conclusion: Etanercept levels of responders and non-
responders were similar and no antibodies to etanercept
were detected with any of the assays. This study
indicates that etanercept is much less immunogenic
compared with the other TNF-blocking agents.
Ankylosing spondylitis (AS) is a chronic inflam-
matory disease, which can result in invalidating
deformities of the joints and spine at an early age.
Until recently, treatment was mainly based on
non-steroidal anti-inflammatory drugs (NSAIDs)
and physical therapy. Most disease-modifying
antirheumatic drugs (DMARDs) do not seem to
be effective in AS, although properly conducted
studies are lacking.1 The introduction of tumour
necrosis factor (TNF) blocking agents, ie, inflix-
imab,2 etanercept3 and adalimumab,4 have changed
the treatment options in AS radically. The
majority of patients with AS, who fulfil the
Assessment of Ankylosing Spondylitis (ASAS)
working group guidelines for anti-TNF treatment,
respond very well. Nevertheless, TNF-blocking
agents still fail to reach efficacy in approximately
30% of patients with AS. A possible explanation for
this failure could be the formation of antibodies,
which results in lower or undetectable serum levels
of the biological agent.
For etanercept, however, it is unclear whether a
relation between clinical response and the forma-
tion of antibodies is present in patients with AS. In
addition, many questions concerning immunogeni-
city have not yet been answered and different
methods of detection of anti-etanercept antibodies
are being used, which makes the results difficult to
compare.5 6
In our previous studies, we demonstrated a
correlation between clinical response and serum
trough infliximab levels, adalimumab levels and
the onset of antibodies against these drugs.7 8 In
this study, we used the same approach as in our
previous studies to investigate the relation
between clinical response, functional etanercept
levels and the detection of anti-etanercept anti-
bodies in patients with AS. Additionally, in a few
patients the etanercept levels were measured daily
to investigate their course over time.
PATIENTS AND METHODS
Patients and study protocol
Consecutive patients with AS, attending the out-
patient clinics of the Jan van Breemen Institute or
of the VU University Medical Center, who were
scheduled for treatment with etanercept were
included and followed prospectively. All patients
with AS fulfilled the modified New York criteria
and started using etanercept according to the ASAS
consensus statement on the initiation of TNF-
blocking agents in AS.9 According to this ASAS
consensus, patients must have an insufficient
response to non-steroid anti-inflammatory drugs
(NSAIDs) and a Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) above 4 (0–10
scale) before starting treatment with etanercept.
After tuberculosis was excluded by means of a
tuberculin skin test and chest x rays, subcutaneous
injections with etanercept 25 mg were taken twice
a week. Concomitant medication remained unal-
tered for at least 3 months after the start of
etanercept treatment. Demographic data collected
at baseline were recorded from medical histories
and patient medical records. The study was
approved by the medical ethical committees of
the two institutions, and all patients gave their
written informed consent.
Outcome measures
Data were collected at baseline and after 3
and 6 months of treatment. During every visit
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questionnaires such as the BASDAI, Patient Global Disease
Activity score and Bath Ankylosing Spondylitis Functional
Index (BASFI) were obtained, and after 3 months patients were
checked as to whether they met the ASAS response criteria.
The primary outcome measure was clinical response after
3 months of treatment with etanercept, according to the
International ASAS Consensus Statement for the use of TNF
agents in patients with AS, which is equivalent to the Dutch
guidelines for continuation of TNF-blocking agents.1 9–11 In this
consensus statement, ASAS response was defined as a 50%
improvement or as an absolute improvement of 2 points of the
BASDAI (0–10 scale) and an expert opinion in favour of
continuation of treatment after 3 months. Routine laboratory
tests (erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) levels) were performed. A CRP value below 8.0 mg/litre
was considered to be normal.
Etanercept levels and antibodies against etanercept were
measured in patient sera at baseline and after 3 and 6 months.
Furthermore, in five patients serum etanercept levels were
measured daily between two consecutive subcutaneous injec-
tions.
Assessment of functional serum etanercept levels
Etanercept levels were measured by means of a newly developed
ELISA, based on the principle that etanercept is captured
through its ability to bind TNF (Sanquin, Diagnostic Services,
Amsterdam, The Netherlands). The sensitivity of detection is
1 ng/ml ( = 0.001 mg/litre).
In short, a mouse monoclonal antibody directed against TNF
(CLB TNF/5) was coated overnight at room temperature
(0.2 mg/well) onto flat-bottomed microtitre plates.
Recombinant TNF (5 ng/well) in high-performance ELISA
(HPE) buffer (Sanquin) was added and remained in place for
1 h. After washing the plates with phosphate buffered saline/
0.02% Tween, patient serum samples were added in different
dilutions in HPE buffer and incubated for 1 h at 37uC. Plates
were washed with phosphate buffered saline (PBS)/0.04%
Tween, and incubated with biotinylated polyclonal rabbit
antibodies against etanercept in 100 ml HPE buffer for 1 h at
37uC. Subsequently, after washing the plates, poly(horseradish
peroxidase)-conjugated streptavidin was added (30 min at
30uC), followed by incubation with tetramethylbenzidine
(TMB). The reaction was stopped with 2 M H2SO4.
Absorption at 450 nm was determined, and results were related
to a titration curve of etanercept, which was present in each
plate. Functionally active etanercept was measured because of
its ability to bind TNF.
Assessment of antibodies against etanercept
Two-site assay
Anti-etanercept antibodies were determined by a two-site assay
in the following manner: etanercept coupled to Sepharose
(100 mg/100 ml) was used to bind etanercept-specific antibodies
from 1 ml of patient serum, diluted in PBS/bovine serum
albumen (BSA) (0.3%)/Tween (0.2%), during an overnight
incubation on a rotator. After removal of non-bound serum
components by washing, 125I-radiolabelled etanercept (,1 ng
per test) was added, followed by a second overnight rotating
incubation in Freeze buffer (Sanquin). The non-bound radi-
olabel was washed off, and test results were compared to a
calibration curve made of serum from an etanercept-vaccinated
rabbit (fig 1). Cut-off level for a positive signal was set at 0.95%
binding (mean+3SD of the pre-treatment values).
Antigen binding test
Additionally, testing for antibodies was carried out by using an
antigen binding test, which is in principle similar to the tests we
routinely use for detection of antibodies against infliximab.12 13
Pepsin-treated 125I-radiolabelled etanercept was used for the
detection of antibodies. The same rabbit-derived calibration
curve as applied in the two-site assay was used for the
interpretation of patient results. Cut-off level for a positive
signal was set at 1.07% binding (mean+3SD of the pre-
treatment values).
Statistical analysis
The last observation was carried forward in patients who had
dropped out before 6 months of treatment, due to ASAS non-
response, adverse events, or loss to follow-up.
Data were expressed as mean (SD) or median (interquartile
range) where appropriate. The distribution of variables was
tested for normality and transformed if possible. Independent
Student t tests were used for variables with a normal
distribution and nonparametric tests (Wilcoxon signed-rank
test or Mann–Whitney U test) for skewed variables. Pearson x2
tests were conducted for dichotomous variables.
Logistic regression analyses were conducted to examine
associations between ASAS response and serum etanercept
level, and were corrected for the possible influence of demo-
graphic, clinical and laboratory variables. Subsequently, a linear
regression model was used to investigate whether serum
etanercept levels were associated with any of the demographic,
clinical or laboratory variables. The following variables were
tested: gender, age, ethnicity, body mass index (BMI) and
Human leukocyte antigen (HLA) B27, baseline bodyweight,
baseline BMI, decrease of Patient Global Assessment score,
absolute decrease of ESR and CRP level.
Calculations were made using SPSS V14.0 software (SPSS
Inc., Chicago, Illinois, USA). The threshold for significance was
set at p,0.05.
RESULTS
A total of 53 patients were included in this study during the
period July 2004 to March 2006. The demographic data and
baseline characteristics are shown in table 1.
Bias due to missing data was excluded, as ASAS response did
not differ between patients with available data and those with
missing data at 6 months.
Treatment with etanercept resulted in significant clinical
improvement after 3 and 6 months, when compared to baseline
(table 1). The mean BASDAI, Patient Global Disease Activity
score, BASFI and ESR were even lower after 6 months of
treatment.
Baseline characteristics did not differ significantly for
responders and non-responders (table 2).
After 3 months of treatment, 40 of the patients (76%) met
the ASAS response criteria.
The etanercept levels were measured in 48 patients after
3 months of treatment and in 41 patients after 6 months of
treatment: 10 of 41 samples turned out to be samples from
ASAS non-responders. These patients should have stopped
treatment with etanercept after 3 months because of insuffi-
cient improvement of the BASDAI. However, they continued
their treatment based on the expert opinion of the rheumatol-
ogist.
At baseline serum etanercept levels were undetectable, mean
serum etanercept levels were 2.7 mg/litre (SD 1.2 mg/litre) and
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3.0 mg/litre (SD 1.0 mg/litre) after 3 and 6 months of
treatment respectively. In each patient etanercept levels could
be measured and were within the same range (fig 2). The mean
etanercept levels of responders and non-responders were similar,
which could be explained by the fact that antibodies against
etanercept were not detected in these patients with any of the
assays (table 2 and fig 2). As well as the lack of association
between clinical response and serum etanercept levels, there was
also no significant association between gender, age, ethnicity,
HLA B27, baseline bodyweight, baseline BMI, decrease of
Patient Global Assessment score, absolute decrease of ESR and
CRP level and serum etanercept levels.
In addition, in five patients etanercept levels were measured
at daily intervals between two subsequent injections with a
mean of 3.5 mg/litre, SD 1.2 mg/litre and a variance of 1.5.
Furthermore, sera of six non-responders were taken 3 months
after the final etanercept injection and, as expected, etanercept
was no longer present in these sera and antibodies against
etanercept could not even be detected in these patients.
Adverse events
One patient had an adverse reaction of flushing and dyspnoea
after 2 months of treatment with etanercept. Another patient
developed urticaria and atopic dermatitis after 27 months of
treatment with a pre-filled syringe of etanercept, however, this
patient showed none of these symptoms after re-treatment
with etanercept in the form of lyophilised powder. Both
patients had previously developed an infusion reaction to
infliximab after which they had switched to etanercept. No
antibodies against etanercept were detected in any of the
patients with adverse reactions.
DISCUSSION
In all, 76% of the patients with AS were classified as responders
to etanercept after 3 months of treatment, which is comparable
to the response rate observed in clinical trials. No correlation
was found between etanercept levels, formation of antibodies
against etanercept and clinical response. All patients had
detectable serum levels of etanercept and no antibodies against
etanercept were found. Interestingly, there seemed to be no
difference in mean etanercept levels and the onset of antibodies
against etanercept between responders and non-responders.
These findings are in contrast with our previous studies with
infliximab8 13 and adalimumab7 in rheumatoid arthritis RA and
AS, where we found a strong corrrelation between decreased
response and the onset of antibodies against TNF-blocking
agents. These antibodies against TNF-blocking agents often
resulted in low or absent serum levels of these drugs, which
would explain the decrease in efficacy, but apparently this is not
the case with etanercept. Therefore, this study seems to confirm
the hypothesis that etanercept is less immunogenic than other
TNF-blocking agents.
Although etanercept levels have not yet been correlated with
clinical response, some studies do report on the detection of
antibodies against etanercept. In these, etanercept has been
labelled as having antibody formation in less than 6% of the
cases and no clear relation to clinical response was detected.5 6 14
These discrepancies regarding anti-therapeutic drug antibodies
could be explained by the use of different detection methods.
ELISA is known to give more false positive signals than antigen
binding assays, and it is therefore difficult to compare other
results with our method. The detection method for anti-
etanercept antibodies used by our laboratory may be regarded as
not very sensitive. However, this does not agree with the fact
that functional etanercept levels could be measured in all
patients, because the presence of antibodies would have resulted
Figure 1 Calibration curve of rabbit anti-etanercept serum as a positive
control for the two-site assay.
Table 1 Demographic data and baseline characteristics
Variables Baseline 3 Months 6 Months
Males (number, %) 40 (76)
Age (years) 41 (11)
Caucasian (number, %) 45 (85)
BMI 25 (4.4)
HLA B27 + (number, %) 44 (88)
Peripheral arthritis (number, %) 28 (53)
BASDAI 6.4 (1.3) 3.1 (2.0)* 2.5 (1.7)*
Patient Global Disease Activity score 7.2 (1.9) 3.2 (2.4)* 2.5 (2.1)*
BASFI 6.2 (2.1) 4.1 (2.5)* 3.5 (2.5)*
ESR (median, range) 22 (1–114) 5 (1–58)* 4 (1–33)*
CRP (median, range) 17 (1–92) 4 (1–44)* 4 (1–74)*
Serum etanercept levels 0 2.7 (1.2) 3.0 (1.0)
Antibodies to etanercept 0 0 0
Except where indicated otherwise, the values are the mean (SD). Mean serum etanercept and antibodies to etanercept levels are in
mg/litre. Normal CRP ,8.0 mg/litre; normal ESR ,10 mm/h.
*Significance level: p,0.001.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index (0–10); BASFI, Bath Ankylosing Spondylitis Functional Index (0–10);
BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA B27, human leukocyte antigen B27.
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in an enhanced clearance and removal of etanercept.
Furthermore, similar techniques for measuring functional
etanercept levels and detecting of antibodies against etanercept
were proven to be sensitive in our previous studies with other
TNF-blocking agents.
Several arguments are in favour of the hypothesis that
etanercept shows less immunogenicity compared with other
TNF-inhibitors. Firstly, etanercept has a less immunogenic
structure compared with the other TNF-blocking agents.
Etanercept is a dimeric fusion protein consisting of two TNF
receptors, linked to the Fc portion of an IgG1. Only the fusion
part of the molecule can contain immunogenic epitopes.
Infliximab is a chimerical monoclonal IgG1 antibody against
TNFa, partly consisting of murine protein. Adalimumab is a
fully human monoclonal antibody against TNFa. These
monoclonal antibodies have more epitopes within the variable
region of the antibody to which an immune response can be
directed. Secondly, major fluctuations in serum levels may
precipitate an immune response and the development of
antibodies against the TNF-blocking agent.15 This is mainly
the case in treatment with infliximab, which is administered
once every 6 to 8 weeks. Treatment with etanercept, however,
produces stable levels between the two injections and is dosed
much more frequently, which is in line with previous
findings.16–19 The variance of 1.5 of the etanercept levels
measured at daily intervals between two subsequent injections
measured in our five patients was very low, compared with the
variance of all serum trough infliximab levels measured in our
previous study, which was 80. The overall variance of all
etanercept levels was 1.3, which is also very low. Thirdly, there
may be different mechanisms for non-response. Theoretically,
non-responders can be divided into two categories: true non-
responders, whose illness is not mainly caused by excess
production of TNFa, and non-responders whose illness is
caused by inadequate blocking of TNFa. The latter can be
caused by enhanced clearance or as a result of inadequate
dosing.
A dose–response relation of etanercept in AS has not been
investigated previously. There is a possibility that small
differences in etanercept levels could not be found because of
the random timing of sampling between two injections. The
most important argument against this view is probably the
observation that etanercept levels, measured at several time
intervals between the two subsequent injections in the five
patients, were quite stable. Furthermore, other authors have
confirmed that etanercept levels are likely to be stable between
two injections.18 Additionally, the mean etanercept levels were
equal in responders and non-responders and this measurement
error would influence both groups in the same way.
In summary, all patients with AS had detectable etanercept
levels, regardless of whether they were responders or non-
responders. In contrast with previous studies with other TNF-
blocking agents, no antibodies against etanercept were detected
with any of the assays. This study indicates that immunogeni-
city does not play an important role in explaining the non-
response of patients with AS to treatment with etanercept.
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Table 2 Baseline characteristics and baseline ESR, CRP and etanercept levels after 3 months of treatment
for ASAS responders and non-responders
Variables
Responders
(n = 40)
Non-responders
(n = 13) p Value
Male gender (number, %) 29 (73) 11 (85) 0.38
Age (years) 41 (11.2) 41 (8.8) 0.82
Caucasian (number, %) 36 (90) 9 (69) 0.07
BMI 25 (4.8) 24 (3.1) 0.53
HLA B27+ (number, %) 34 (90) 10 (83) 0.57
Peripheral arthritis (number, %) 21 (53) 7 (54) 0.99
BASDAI 6.4 (1.3) 6.2 (1.4) 0.57
Patient Global Disease Activity (VAS) 7.1 (1.5) 7.4 (1.9) 0.31
BASFI 6.2 (2.1) 6.2 (2.2) 0.86
ESR (median, range) 22 (1–114) 22 (1–87) 0.82
CRP (median, range) 18 (1–91) 10 (1–92) 0.45
Etanercept level (mg/litre) 2.7 (1.3) 2.8 (1.1) 0.50
Except where indicated otherwise, the values are the mean (SD).
ASAS, Assessment in Ankylosing Spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index (0–10); BASFI, Bath
Ankylosing Spondylitis Functional Index (0–10); BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation
rate; HLA B27, human leukocyte antigen B27; VAS, visual analogue scale.
Figure 2 Etanercept levels (mg/litre) for Assessment of Ankylosing
Spondylitis (ASAS) responders and non-responders after 3 months of
treatment.
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